GLUT2 Immunoreactivity in Gomori-positive Astrocytes of the Hypothalamus
Department of Anatomy, Howard University College of Medicine, Washington, District of Columbia
Correspondence to: John K. Young, Ph.D., Dept. of Anatomy, Howard University College of Medicine, 520 W Street, N.W., Washington, DC 20059. E-mail: jyoung{at}howard.edu
![]() |
Summary |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key Words: GLUT2 glucose arcuate nucleus mitochondria oxidative stress
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Increased glucose metabolism may be one factor underlying an enhanced oxidative stress in the arcuate nucleus. Several studies have reported the presence of high-capacity GLUT2 glucose transporter proteins in arcuate astrocytes and in arcuate tanycytes (Leloup et al. 1994; Ngarmukos et al. 2001
; García et al. 2003
). High levels of the mRNA for GLUT2 transporters have also been detected in the arcuate nucleus (García et al. 2003
; Li et al. 2003
).
In the liver and islets of Langerhans, these high-capacity, low-affinity GLUT2 glucose transporter proteins represent a portion of the glucose-sensing mechanism of hepatocytes and ß cells. In the retina, GLUT2 transporters allow glial cells to take up and metabolize glucose at a substantially greater rate than that of neurons (Poitry-Yamate and Tsacopoulos 1992; Watanabe et al. 1994
). In the hypothalamus, GLUT2 transporters seem functionally significant, because intraventricular infusions of antisense oligonucleotides that bind GLUT2 mRNA alter the neuroendocrine response to hypoglycemia (Leloup et al. 1998
; Wan et al. 1998
).
The overall distribution of arcuate astrocytes immunoreactive for GLUT2 transporters reported in one study appears to match the anatomical distribution of GP astrocytes (Young et al. 1990; Leloup et al. 1994
). Chronic exposure of neural tissue to hyperglycemia does provoke the type of oxidative stress and mitochondrial impairment that is thought to damage mitochondria in GP astrocytes (Yang et al. 1998
; Schmeichel et al. 2003
). Thus, an increased rate of glucose uptake and oxidation could conceivably be one factor underlying the development of the GP phenotype in arcuate astrocytes.
An initial step in examining this hypothesis is to determine if some or all GP astrocytes stain positively for the GLUT2 glucose transporter protein. That is the main goal of this study.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Immunocytochemistry for GLUT2 Transporters
Free-floating vibratome sections, prepared using an Oxford vibratome (Vibratome, St. Louis, MO), were stained to demonstrate GLUT2 immunoreactivity. Sections were first all washed in PBS-normal goat serum and then incubated overnight at 4C with either the antibody to GLUT2 or with nonimmune rabbit serum.
GLUT2 immunoreactivity was demonstrated by use of a polyclonal rabbit antibody generously provided by Dr. William Pardridge. This antibody identified GLUT2 immunoreactivity in arcuate astrocytes in a recent publication (Ngarmukos et al. 2001). The antibody was raised in rabbits against a synthetic peptide, corresponding to a 13-amino acid carboxy-terminal sequence of the GLUT2 protein, that was then conjugated to bovine thyroglobulin. To eliminate nonspecific reactivity to thyroglobulin-like epitopes, the antibody was diluted 1:100 in 1 ml of Tris buffer, 5 mg of bovine thyroglobulin was added (Sigma Chemical Co.; St. Louis, MO), and the mixture was shaken at 37C for 60 min and spun at 10,000 x g to produce a pellet, which was discarded (Cramer et al. 1992
). Preliminary trials indicated that the optimal dilution of the antibody for staining was 1:900. As an additional control, an aliquot of antibody, diluted 1:900, was preabsorbed by shaking at 37C with the GLUT2 peptide (Biogenesis, Inc., Kingston, NH). Vibratome sections were incubated in this antibody or in nonimmune rabbit serum, as described above, to demonstrate GLUT2 immunoreactivity.
After this, sections were washed in PBS-0.1% Triton X-100, incubated for 30 min in biotinylated goat anti-rabbit IgG (Vectastain ABC kit; Vector Laboratories, Burlingame, CA), and washed once more in PBS-0.1% Triton X-100. To nullify endogenous sources of pseudoperoxidase such as the cytoplasmic granules of GP astrocytes, sections were then incubated for 30 min in PBS-0.3% hydrogen peroxide, followed by washing in PBS and a 60-min incubation in avidin-biotin-peroxidase complex. Immunoreactivity was then localized via the production of a brown precipitate of diaminobenzidine (DAB) at the sites of peroxidase-labeled antibody by exposing the sections to a 0.05% solution of DAB plus 0.03% hydrogen peroxide for 15 min (Young et al. 2000). Subsequently, vibratome sections were dehydrated in alcohol and flat embedded between two plastic cover slips in JB-4 methacrylate resin (Polysciences, Inc.; Warrington, PA). These sections were then glued to methacrylate blocks using cyanoacrylate glue and were cut at a thickness of 1 µm using dry glass knives and a JB-4 microtome. Semithin sections were dried down onto gelatinized slides and briefly (20 s) counterstained with 0.1% toluidine blue in 0.2 M acetate buffer (pH 4.5) (Young et al. 1990
).
Staining of GP Astrocytes
Several methods were used to stain cytoplasmic GP granules. First, to demonstrate the overall distribution of GP granules, which contain heme-linked iron derived from mitochondria, serial frozen sections of the arcuate region were prepared and every other section was stained with an intensified version of the Perl's reaction for iron. Free-floating sections were immersed in 5% HCl and 5% potassium ferrocyanide for 40 min to generate precipitates of ferric ferrocyanide over GP granules. Sections were then rinsed in phosphate buffer and immersed in 0.1% DAB containing 0.005% hydrogen peroxide for an additional 15 min. This procedure, which uses ferric ferrocyanide to intensify the conversion of DAB into a dark brown precipitate by hydrogen peroxide, demonstrates the minute iron-rich GP granules scattered throughout the arcuate nucleus but leaves other cellular elements unstained (Young 1988). In a number of trials, attempts were made to combine this procedure with immunocytochemistry. However, the highly acid pH required for the Perl's reaction either degraded antigenicity or else dissolved the DAB precipitate, making this reaction unsuitable for staining GP granules either before or after immunocytochemistry.
In an attempt to examine another staining method for GP astrocytes that is more compatible with immunocytochemistry, an approach described by Schipper and Mateescu-Cantuniari (1991) was used. This approach takes advantage of the pseudoperoxidase activity inherent in the heme-linked iron present in GP granules to directly convert DAB into an insoluble precipitate without prior exposure to the reagents of the Perl's reaction. Every other hypothalamic section was incubated in Tris-buffered saline containing 0.05% DAB plus 0.002% hydrogen peroxide for 30 min, and then sections were washed in PBS, mounted on slides, dehydrated, and cover slipped. Numbers of brown-staining clusters of granules, corresponding to GP astrocytes, were compared with counts obtained using the Perl's stain on adjacent brain sections.
To demonstrate GP granules in semithin sections, immunostained 60-µm-thick vibratome sections were flat embedded, sectioned at a thickness of 1 µm, and counterstained with 0.1% toluidine blue in 0.2 M acetate buffer (pH 4.5) so that GP granules appeared bright blue and cellular immunoreactivity retained a brown color attributable to DAB (Young et al. 1990).
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
No GLUT2 immunoreactivity was detected in brain regions dorsal to the hypothalamus or in sections exposed to nonimmune serum or to GLUT2 antibody preabsorbed with GLUT2 peptide (data not shown).
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
An unusual glucose metabolism of GP astrocytes may be one factor provoking oxidative damage and an age-related mitochondrial degeneration in these cells. During episodes of high blood glucose, glucose uptake into cells bearing high-capacity GLUT2 transporters would be increased. An increased glucose metabolism can provoke the type of oxidative stress in both pancreatic ß cells and in neural tissue that is thought to damage mitochondria in GP astrocytes (Yang et al. 1998; Robertson et al. 2003
; Schmeichel et al. 2003
). In contrast, during conditions of hypoglycemia, low-affinity GLUT2 transporters fail to maintain an adequate glucose uptake into cells (Olson and Pessin, 1996
). Hypoglycemia would thus impose another type of metabolic stress upon GLUT2-immunoreactive cells. In this context, it appears significant that GP astrocytes exhibit increased levels of glucose-regulated protein-94, which is normally produced in response to a deficit in glucose uptake (Mydlarski and Schipper, 1993
). To further examine the possible consequences of a specialized glucose metabolism, it would be desirable to determine if bouts of hyperglycemia or hypoglycemia alter the rate of development of mitochondrial degeneration in GP astrocytes in vivo.
GLUT2 immunoreactivity in GP astrocytes may also have implications for the function of adjacent neurons. Neurons in the basomedial hypothalamus show an unusual sensitivity to changes in circulating glucose levels (Tkacs et al. 2000; Young et al. 2000
; Briski and Marshall 2001
). The function of these neurons can in turn be modulated by infusions of lactate (Briski 1999
; Borg et al. 2003
). Because the main source of brain lactate is from the metabolism of astrocyte glycogen, carbohydrate metabolism by astrocytes may have an important modulatory effect upon glucose sensing by the hypothalamus. This proposition is supported by the ability of astrocyte toxins to diminish the effects of 2-deoxyglucose and goldthioglucose upon the hypothalamus (Young, 1988
; Young et al. 2000
; Pow, 2001
).
Many of the glucose-sensing neurons of the hypothalamus appear to be dopaminergic (Briski 1998). We have previously established that GP astrocytes are in close contact with arcuate dopaminergic neurons at the ultrastructural level (Young et al. 1990
). Thus, GP astrocytes have both anatomical and physiological characteristics that would enable them to modify the process of glucose sensing by the hypothalamus.
It would be desirable to determine if GP astrocytes in other brain regions also possess GLUT2 transporters. For example, GP astrocytes can also be detected in the hippocampus (Young et al., 1996; St. Jacques et al. 1999
). It seems reasonable that GP astrocytes in other brain regions would share the phenotypic complement of proteins that they possess in the hypothalamus. An example of such a protein is brain fatty acid binding protein, which is unusually abundant in arcuate GP astrocytes and which also is expressed in GP astrocytes in the hippocampus (Young et al. 1996
). It was not possible, however, to test this proposition in this study because immunoreactivity for GLUT2 transporters was not detected in extrahypothalamic brain regions. This was likely related to the much lower abundance of the mRNA for GLUT2 in cortical and subcortical structures relative to that in the hypothalamus (Li et al. 2003
).
Finally, the age-related damage to mitochondria in GP astrocytes may compromise the function of adjacent neurons. It is known, for example, that a specific blockade of oxidative metabolism in glial mitochondria by fluoroacetate can have serious consequences for the function of nearby neurons (Hülsmann et al. 2000). Also, oxidative damage to astrocyte mitochondria now appears to contribute to neuronal dysfunction in Alzheimer's disease (St. Jacques et al. 1999
; Abramov et al. 2004
). One way to examine this question in the case of GP astrocytes would be to determine if the age-related increase in numbers of GP granules correlates with an altered response to glucose deprivation by neurons of the hypothalamus. If so, an age-related oxidative damage to these glucose-sensitive glia in the hypothalamus may have important implications for hypothalamic function and for the pathophysiology of diabetes mellitus. Clinical data suggest that an impairment of hypothalamic glucose sensing may be present in at least a portion of diabetic patients and may increase the likelihood and damaging effects of episodes of hypoglycemia (Cranston et al. 2001
).
![]() |
Acknowledgments |
---|
![]() |
Footnotes |
---|
![]() |
Literature Cited |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Abramov AY, Canevari L, Duchen MR (2004) ß-Amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24:565575
Borg MA, Tamborlane WV, Shulman GI, Sherwin RS (2003) Local lactate perfusion of the ventromedial hypothalamus suppresses hypoglycemic counterregulation. Diabetes 52:663666
Brawer JR, Stein R, Small L, Cisse S, Schipper HM (1994) Composition of Gomori-positive inclusions in astrocytes of the hypothalamic arcuate nucleus. Anat Rec 240:407415[Medline]
Briski KP (1998) Glucoprivic induction of fos immunoreactivity in hypothalamic dopaminergic neurons. Neuroreport 9:289295[Medline]
Briski KP (1999) Intraventricular lactate infusion attenuates the transactivational effects of the glucose antimetabolite, 2-deoxy-D-glucose, on hypothalamic vasopressinergic neurons. Brain Res 839:341345[CrossRef][Medline]
Briski KP, Marshall ES (2001) Induction of ependymal, glial, and neuronal transactivation by intraventricular administration of the SGLT1 Na+-D-glucose cotransporter inhibitor phlorizin. Neurochem Res 26:783792[CrossRef][Medline]
Cramer SC, Pardridge WM, Hirayama BA, Wright EM (1992) Colocalization of GLUT2 glucose transporter, sodium/glucose cotransporter, and -glutamyl transpeptidase in rat kidney with double-peroxidase immunocytochemistry. Diabetes 41:766770[Abstract]
Cranston I, Reed LJ, Marsden PK, Amiel SA (2001) Changes in regional brain 18F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure. Diabetes 50:23292366
García MDLA, Millan C, Balmaceda-Aguilera C, Castro T, Pastor P, Montecinos H, Reinicke K, et al. (2003) Hypothalamic ependymal-glial cells express the glucose transporter GLUT2, a protein involved in glucose sensing. J Neurochem 86:709724[CrossRef][Medline]
Hülsmann S, Oku Y, Zhang W, Richter DW (2000) Metabolic coupling between glia and neurons is necessary for maintaining respiratory activity in transverse medullary slices of neonatal mouse. Eur J Neurosci 12:856862[CrossRef][Medline]
Lane RH, Crawford SE, Flozak AS, Simmons RA (1999) Localization and quantification of glucose transporters in liver of growth-retarded fetal and neonatal rats. Am J Physiol: Endocrinol Metab 276:E135E142
Leloup C, Arluison M, Lepetit N, Cartier N, Marfaing-Jallat P, Ferre P, Penicaud L (1994) Glucose transporter 2 (Glut 2): expression in specific brain nuclei. Brain Res 638:221236[CrossRef][Medline]
Leloup C, Orosco M, Serradas P, Nicolaidis S, Penicaud L (1998) Specific inhibition of GLUT2 in arcuate nucleus by antisense oligonucleotides suppresses nervous control of insulin secretion. Brain Res Mol Brain Res 57:275280[Medline]
Li B, Xi L, Roane DS, Ryan DH, Martin RJ (2003) Distribution of glucokinase, glucose transporter GLUT2, sulfonylurea receptor-1, glucagons-like peptide-1 receptor and neuropeptide Y messenger RNAs in rat brain by quantitative real-time RT-PCR. Brain Res Mol Brain Res 113:139142[Medline]
Mydlarski MB, Schipper HM (1993) Stress protein co-localization to autofluorescent astrocytic inclusions in situ and in cysteamine-treated glial cultures. Brain Res 627:113121[CrossRef][Medline]
Ngarmukos C, Bauer EL, Kumagai AK (2001) Co-localization of GLUT1 and GLUT4 in the blood-brain barrier of the rat ventromedial hypothalamus. Brain Res 900:18[CrossRef][Medline]
Olson AL, Pessin JE (1996) Structure, function, and regulation of the mammalian facilitative glucose transporter gene family. Annu Rev Nutr 16:235256[CrossRef][Medline]
Poitry-Yamate CL, Tsacopoulos M (1992) Glucose metabolism in freshly isolated Müller glial cells from a mammalian retina. J Comp Neurol 320:257266[Medline]
Pow DV (2001) Visualising the activity of the cystine-glutamate antiporter in glial cells using antibodies to aminoadipic acid, a selectively transported substrate. Glia 34:2738[CrossRef][Medline]
Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H (2003) Glucose toxicity in ß-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:581587
Schipper HM, Mateescu-Cantuniari A (1991) Identification of peroxidase-positive astrocytes by combined histochemical and immunolabeling techniques in situ and in cell culture. J Histochem Cytochem 39:10091016[Abstract]
Schipper HM, Mydlarski MB, Wang X (1993) Cysteamine gliopathy in situ: a cellular stress model for the biogenesis of astrocytic inclusions. J Neuropathol Exp Neurol 52:399410[Medline]
Schmeichel AM, Schmelzer JD, Low PA (2003) Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52:165171
St. Jacques R, Chapman A, Lacaille JC, Mohr C, Schipper HM (1999) Acceleration of ageing-related gliopathic changes and hippocampal dysfunction following intracerebroventricular infusion of cysteamine in adult rats. Neuroscience 90:11031113[CrossRef][Medline]
Tkacs NC, Dunn-Meynell AA, Levin BE (2000) Presumed apoptosis and reduced arcuate nucleus neuropeptide Y and pro-opiomelanocortin mRNA in non-coma hypoglycemia. Diabetes 49:820826[Abstract]
Wan HZ, Hulsey MG, Martin RJ (1998) Intracerebroventricular administration of antisense oligodeoxynucleotide against GLUT2 glucose transporter mRNA reduces food intake, body weight change and glucoprivic feeding response in rats. Nutrition 128:287291[CrossRef]
Wang X, Manganaro F, Schipper HM (1995) A cellular stress model for the sequestration of redox-active glial iron in the aging and degenerating nervous system. J Neurochem 64:18681877[Medline]
Watanabe T, Mio Y, Hoshino FB, Nagamatsu S, Hirosawa K, Nakahara K (1994) GLUT2 expression in the rat retina: localization at the apical ends of Muller cells. Brain Res 655:128134[CrossRef][Medline]
Yang X, Borg LAH, Siman CM, Eriksson UJ (1998) Maternal antioxidant treatments prevent diabetes-induced alterations of mitochondrial morphology in rat embryos. Anat Rec 251:303315[CrossRef][Medline]
Young JK (1988) A glial toxin reduces effects of goldthioglucose upon the hypothalamus and area postrema. Brain Res Bull 20:97104[CrossRef][Medline]
Young JK, Baker JH, Montes MI (2000) The brain response to 2-deoxy glucose is blocked by a glial drug. Pharmacol Biochem Behav 67:233239[CrossRef][Medline]
Young JK, Baker JH, Müller T (1996) Immunoreactivity for brain fatty acid binding protein in Gomori-positive astrocytes. Glia 16:218226[Medline]
Young JK, McKenzie JC, Baker JH (1990) Association of iron-containing astrocytes with dopaminergic neurons of the arcuate nucleus. J Neurosci Res 25:204213[Medline]